Lack of cardiac and high-fat diet induced metabolic phenotypes in two independent strains of Vegf-b knockout mice by Dijkstra, M. H. et al.
Lack of cardiac and high-fat diet induced
metabolic phenotypes in two
independent strains of Vegf-b knockout
mice
M. H. Dijkstra1, E. Pirinen1*, J. Huusko1, R. Kivela¨2, D. Schenkwein1, K. Alitalo2 & S. Yla¨-Herttuala1,3,4
1Department of Biotechnology and Molecular Medicine, A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland,
P.O.Box 1627, FIN-70211 Kuopio, Finland, 2Wihuri Research Institute and Translational Cancer Biology Program, Biomedicum
Helsinki, University of Helsinki, FIN-00290 Helsinki, Finland, 3Science Service Centre, Kuopio University Hospital, P.O. Box 1777,
FIN-70211 Kuopio, Finland, 4Gene Therapy Unit, Kuopio University Hospital, P.O. Box 1777, FIN-70211 Kuopio, Finland.
Vascular endothelial growth factor-B (VEGF-B) has been implicated to play a significant role in coronary
vessel growth and endothelial uptake and transport of fatty acids in heart and skeletal muscle. Additionally,
recent studies have shown that Vegf-b deficiency protects from high-fat diet (HFD)-induced diabetes and
insulin resistance. We compared the cardiac function and the effects of HFD on body composition and
glucosemetabolism in two available Vegf-b knockout (Vegf-b-/- strains)mouse strains side by side with their
respective littermate controls. We found no differences in HFD-induced weight gain, glucose tolerance or
insulin resistance between the Vegf-b-/- strains and their littermate control mice. Furthermore, there was no
difference in basal cardiac function and cardiac expression of genes involved in glucose or fatty acid
metabolism between the Vegf-b-/- strains and their littermate control mice. We conclude that VEGF-B is
dispensable for normal cardiac function under unstressed conditions and for HFD-induced metabolic
changes.
A
s the prevalence of cardiovascular diseases increases together with obesity and type 2 diabetes, targeting a
growth factor involved in cardiac metabolism, angiogenesis and whole body metabolism could have
significant therapeutic implications. Vascular endothelial growth factor-B (VEGF-B), the most abundant
VEGF in the heart1, mediates its signaling via binding to VEGF-Receptor 1 (VEGF-R1/Flt-1)2 and neuropilin 1
(Nrp1)3 receptor. VEGF-B has been suggested to play an important role in cardiac metabolism4,5, but the
mechanisms are still largely unknown. Long-term Vegf-b167 over-expression in the heart of transgenic mice
elevated ceramide levels and decreased triglyceride (TG) levels4. In contrast, Vegf-b knockout mice showed
decreased fatty acid (FA) and increased glucose uptake in the heart5. More recently VEGF-B was shown to
stimulate coronary vessel growth and arterialization6–9 and to induce a shift from FA oxidation towards glucose
oxidation in the heart10.
To investigate the role of VEGF-B two constitutive Vegf-b-/- knockout models have been generated. TheVegf-b
deficient mice of both strains were healthy and fertile, and had minimal phenotypes. The mice published by
Bellomo et al.11 showed decreased heart size, reduced left ventricle (LV) wall thickness and impaired recovery
from experimentally induced myocardial ischemia via transient coronary occlusion ex vivo11 (here referred to as
Bellomo mice), while the other Vegf-b-/- strain (Aase mice) displayed a prolonged PQ interval in electrocardio-
grams, indicating a delayed atrioventricular impulse conduction12. Despite these minor differences in the phe-
notypes, both publications on the Vegf-b-/- models speculated that Vegf-b has a protective role in the normal or
ischemic heart. Such an idea is supported by experiments with adenoviral VEGF-B gene delivery and VEGF-B
protein delivery, indicating angiogenic effects in the ischemic heart7,8.
Recent reports have drawn attention to the findings showing that the AaseVegf-b-/- mice gainmore weight than
control mice by shunting lipids more effectively to white adipose tissue (WAT)5, and that VEGF-B neutralization
results in better glucose and insulin responses13. But as suggested by Carmeliet et al.14 confirmation of the anti-
diabetic, yet obese, phenotype in another Vegf-b-/- strain would strengthen these findings. Further concern was
raised by the results of Kivela¨ et al.10, who found no difference in cardiac or skeletal muscle fatty acid uptake
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between wildtype and Vegf-b-/- rats. Here we report the first direct
side by side comparison of body composition, glucose metabolism
and cardiac function in both of the available Vegf-b-/- strains11,12
under identical unstressed environmental conditions. Our results
show that, despite different targeting constructs and previously
observed findings, Vegf-b deficiency causes only minor, if any,
changes in cardiac phenotype and high-fat diet (HFD)-induced
metabolic responses.
Results
Confirmation of Vegf-b deletion and sequence of the Vegf-b
targeting constructs. We first confirmed that both littermate
control groups expressed similar levels of VEGF-B (Fig. 1a and b).
To confirm that neither Vegf-b-/- strain expresses VEGF-B, we
analyzed the VEGF-B mRNA expression in the heart (Fig. 1). The
VEGF-B exon 1-2 RT-PCR indicated at least 10,000 fold decreased
VEGF-B mRNA concentration in the hearts of both gene targeted
mouse strains (Fig. 1a). However, an unexpectedly high amount of
signal was obtained from the Aase strain by RT-PCR using primers
from VEGF-B exons 6 and 7 (Fig. 1b). To rule out the possibility of a
NeoR-VEGF-B exon 6-7 fusion protein expression in the Aase mice,
the inserted NeoR knockout construct and its junctions with the
Vegf-b gene were sequenced (Fig. 1c). Sequence analysis verified
the presence of polyadenylation signals and a stop codon in the
NeoR construct, as expected, rendering the generation of NeoR-
VEGF-B exon 6-7 fusion protein highly unlikely (Fig. 1c). Further
analysis of the junction sites confirmed the correct insertion of the
targeting construct in exon 3 and upstream of exon 5 and that the
NeoR construct contained the NeoR gene preceded by a PGK
promoter. Because the 39 homology arm used to create the Aase
Vegf-b-/- mice contains the sequence of exon 6 but not exon 7
sequences12, the presence of the exon 6-7 mRNA, detected by RT-
PCR, further verifies a bona fide insertion of the targeting construct
in the genomic DNA. Absence of any residual VEGF-B exon 6-7
expression in the Bellomo Vegf-b-/- mice implies that the b-geo
construct has successfully replaced exons 3-6 (note that exon 6 is
named exon 7 in the original report by Bellomo11). Sequencing of
both the 39 and 59 insertion sites of the b-geo cassette in the Bellomo
Vegf-b-/- mice showed that the construct was properly integrated into
the Vegf-b genomic DNA (Fig. 1c).
No cardiac phenotype of Vegf-b-/- strains on standard diet. To
compare the cardiac phenotypes of Bellomo and Aase Vegf-b-/-
mice on standard diet, we performed echocardiography to
determine the left ventricular volume (LV Vol) in diastole (d) and
systole (s), the thickness of LVwall (LVAW; d, s, LVPW; d, s) and LV
mass, LV internal diameter (LVID; d, s) and functionality of the heart
as indicated by the ejection fraction (EF) and fractional shortening
(FS; Table 1). The results showed no differences in these parameters
when theVegf-b-/- mice were compared to their respective controls or
to each other (Table 1). Furthermore, no differences were found
between the electrocardiography recordings between the study
groups (Table 1).
Response to aWestern-type diet.To investigate possible differences
in body weight and glucosemetabolism as reported for the AaseVegf-b-/-
mice5,13, we analyzed the response of the Bellomo Vegf-b-/- mice to a
Western-type diet (WD; 42% calories from fat), starting at 14 weeks
of age. The control group was maintained on a standard diet (SD).
UponWD, no difference was observed in body weight in the Bellomo
Vegf-b-/- mice versus their littermate controls. However, the SD
Figure 1 | VEGF-B mRNA expression and structure of the targeting constructs. (a) VEGF-B exon 1-2 mRNA expression. (b) VEGF-B exon 6-7 mRNA
expression. (c). Overview of theAase and BellomoVegf-b targeting constructs in the correspondingVegf-b-/- mice. Red arrow indicates the sequenced area.
n57, Kruskal-Wallis with Dunn’s post hoc test (a and b). *p,0.05, **p,0.01 ***p,0.001 ns5 non significant. Results are expressed as mean 6 S.E.M.
www.nature.com/scientificreports
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Bellomo Vegf-b-/- mice were significantly heavier between 12-21
weeks of age (Fig. 2a, p50.0375 at 13 weeks and p50.0171 at 21
weeks on SD), but the difference disappeared by 23 weeks of age. Fat
analysis after WD by magnetic resonance imaging (MRI) showed no
changes in body fat percentage (Fig. 2b) or amount of fat normalized
to body size (Fig. 2c). Furthermore, neither the intraperitoneal
glucose tolerance test (IPGTT; Fig. 2d, e, g and h) nor the
intraperitoneal insulin tolerance test (IPITT; Fig. 2f and i) showed
differences between the littermate control and Vegf-b-/- mice on SD or
WD. Plasma TG, cholesterol and serum free FA levels did not differ
between the littermate controls and Bellomo Vegf-b-/- mice before or
after SD or WD (Table 2). There was a similar significant increase in
cholesterol levels with age regardless of the diet (p,0.0001) in the
littermate controls and Bellomo Vegf-b-/- mice. TGs and free FAs
remained unchanged. Food intake was similar in both strains on
both diets (Table 2).
Response to a high-fat diet.We also studied bothVegf-b-/- strains on
a 60% HFD, including their respective littermate controls, and
analyzed their response to IPGTT and IPITT according to the
published protocol13 (Fig. 3). No differences in glucose tolerance
were observed between any of the strains after 15 weeks on HFD
(Fig. 3a, b). Similarly, IPITT did not reveal any major changes in
insulin sensitivity except that the Aase littermate control mice
showed lower glucose levels at 20 minutes (Fig. 3c, Aase WT
versus Aase Vegf-b-/- p,0.01, Aase WT versus Bellomo WT
p,0.05) and 40 minutes (Fig. 3c, Aase WT versus Aase Vegf-b-/-
p,0.05) after the insulin injection. These results were not
surprising considering that the body weight gain of these mice was
similar at the time of IPGTT (15 weeks on 60% HFD or WD; Fig. 3d
and data not shown). Additionally, no difference was detected in
insulin stimulated GLUT4 translocation between Bellomo Vegf-b-/-,
Aase Vegf-b-/- and littermate control hearts (Fig. 3e) or skeletal
muscles (Fig. 3 f) on SD.
Cardiac gene expression profile on high-fat diet.Differences in the
expression levels of mRNAs encoding key mitochondrial and fatty
acid transport proteins (FATPs) between the Vegf-b knockout and
control mice were reported5. They found that the fatty acid transport
protein 4 (Fatp4) and Fatp3 are regulated by VEGF-B in the heart.
However, in a subsequent study using Vegf-b transgenic and
knockout rats, Vegf-b regulation of Fatp3 was not detected5,10. In
the present study, we did not detect differences in either FATP3 or
FATP4 mRNA levels between any of the Vegf-b-/- strains after HFD
(Table 3) or in Bellomo Vegf-b-/- on SD and WD (data not shown).
We also analyzed expression of a set of metabolic genes involved in
glucose metabolism, FA oxidation, FA synthesis and transcriptional
regulation of metabolism in the heart (Table 3) but Vegf-b deficiency
did not have any significant impact on the expression level of these
key genes of metabolic pathways on HFD.
Discussion
This is the first time Vegf-b knockout strains have been available for
direct comparison of body composition, cardiac function and glu-
cose and insulin tolerance in identical environmental circumstances.
The strength of this side by side comparison of mouse lines is that
external factors which affect the sensitive tolerance tests used, such as
housing conditions, stress and handling, or methodological differ-
ences were minimized. Both strains were tested for body composi-
tion, glucose and insulin tolerance and cardiac function.
We report the surprising finding that neither of the two Vegf-b
knockoutmice showed differences in bodyweight gain, amount of fat
or insulin resistance upon WD or HFD feeding. The only difference
found was that on SD, the Bellomo Vegf-b-/- mice were significantly
heavier at the age 12–20 weeks compared to littermate controls, but
this difference tended to disappear with aging. This finding is similar
as to the 15%weight gain of AaseVegf-b-/- mice on SD at 16–18 weeks
of age5.
Previously, Bellomo et al. reported smaller hearts and decreased LV
thickness in Bellomo Vegf-b-/- mice as compared with control mice11
while Aase et al. reported no differences in heart size and LV thickness
but instead a prolonged PQ interval in Aase Vegf-b-/- mice in basal
state12. Here we did not observe any differences in the cardiac struc-
tural or functional parameters measured between or within the two
Vegf-b-/- strains. This shows that in basal state under the same
unstressed circumstances the cardiac phenotype and functionality is
not affected by Vegf-b deficiency in contrast to previous findings11,12.
At the molecular level, the expression of FATP3 and FATP4 was
not changed in Vegf-b-/- hearts after HFD. In rats, only FATP4 was
found regulated by Vegf-b10. This suggests that previously observed
FATP changes likely reflected the metabolic state of the mice rather
than the deficiency of the Vegf-b gene. Nevertheless it has been
shown that Flt-1-TK-/- and Nrp-1-EC-/- mice have decreased Fatp
expression on SD as well5, showing that VEGF-B signaling may be
important in FATP regulation.
Table 1 | Cardiac phenotype of Bellomo and Aase Vegf-b-/- mice
Phenotype Parameter Aase WT Aase Vegf-b-/- Bellomo WT Bellomo Vegf-b-/-
Heart function EF (%) 56.18 6 9.45 65.57 6 13.72 62.75 6 6.09 66.77 6 9.90
FS (%) 29.31 6 5.94 36.57 6 9.86 33.66 6 4.29 36.91 6 7.13
Heart size LVAW; d (mm) 0.84 6 0.14 0.93 6 0.15 0.95 6 0.10 0.92 6 0.13
LVAW; s (mm) 1.21 6 0.14 1.37 6 0.33 1.38 6 0.14 1.45 6 0.21
LVID; d (mm) 4.24 6 0.33 3.95 6 0.14 4.05 6 0.16 3.94 6 0.17
LVID; s (mm) 3.01 6 0.48 2.50 6 0.36 2.69 6 0.23 2.49 6 0.38
LVPW; d (mm) 0.72 6 0.12 0.80 6 0.14 0.77 6 0.11 0.79 6 0.10
LVPW; s (mm) 1.08 6 0.16 1.20 6 0.28 1.20 6 0.17 1.23 6 0.118
LV Vol; d (ml) 80.88 6 14.52 67.90 6 5.67 72.24 6 6.70 67.73 6 6.69
LV Vol; s (ml) 36.40 6 14.31 22.92 6 8.64 27.05 6 5.60 22.99 6 9.27
LV mass 124.92 6 23.39 129.88 6 15.01 132.93 6 12.09 125.94 6 22.15
ECG PQ interval (ms) 43.97 6 2.41 42.59 6 3.65 43.80 6 1.25 43.30 6 1.12
QRS interval (ms) 10.41 6 0.48 10.06 6 0.20 10.43 6 0.46 10.86 6 0.27
QT interval (ms) 37.50 6 3.52 41.11 6 2.63 41.25 6 2.36 39.93 6 0.97
P amplitude (mV) 1.250 6 0.25 0.8376 6 0.24 1.221 6 0.12 1.261 6 0.12
R amplitude (mV) 10.11 6 0.59 10.43 6 0.75 9.495 6 0.74 10.08 6 0.45
Heart rate (bpm) 366.0 6 32.17 400.3 6 20.08 439.1 6 18.27 441.6 6 19.11
Heart function determined by ejection fraction (EF) and fractional shortening (FS). Heart size in diastole (d) and systole (s) represented by left ventricular anterior wall (LVAW) thickness, left ventricular internal
diameter (LVID), left ventricular posterior wall (LVPW) thickness, left ventricle (LV) volume and LV mass in Aase and Bellomo VEGF-B-/- and littermate control mice. ECG recordings are shown as PQ, QRS and
QT interval, heart rate in beats per minute (bpm) and amplitudes of P and R peak. Results are expressed as mean 6 S.E.M. n54–9.
www.nature.com/scientificreports
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Aase Vegf-b-/-, Bellomo Vegf-b-/-and Bellomo littermate control
mice displayed similar glucose metabolism responding equally dur-
ing IPGTT and IPITT. Interestingly, the Aase littermate controls
responded differently than Bellomo littermate controls during
IPITT. Thus it is tempting to speculate that the reason for this minor
difference is the background of the mice studied. When considering
the production and backcrossing of these mice it is known that both
strains have been produced similarly by injecting targeted ES cells of
129/Ola12 (new nomenclature: 129P2) or 129/SvJ11 (new nomenclat-
ure: 129X1) into C57BL or C57BL/6J blastocysts, respectively. The
resulting Bellomo Vegf-b-/- chimeras were backcrossed into C57BL
background from that moment while for the Aase mice the back-
Figure 2 | Body composition and glucose metabolism in Bellomo Vegf-b-/- mice onWestern-type diet. (a). Body weight during the course of Western-
type diet (WD) and standard diet (SD) feeding. (b). Body fat percentage and (c) body fat normalized to body size after WD. (d). Glucose and (e) insulin
levels during intraperitoneal glucose tolerance test (IPGTT) on SD. (g). Glucose and (h) insulin levels during IPGTT onWD. The glucose dose used was
2 mg/g body weight. (f). Intraperitoneal insulin tolerance test (IPITT) with the insulin dose of 0.25 mU/g body weight on SD and (i) onWD in Bellomo
Vegf-b-/- and littermate control mice. The statistical analyses were performed with one-way ANOVA (a) or Student’s t-test (b to i). Results are expressed as
mean 6 S.E.M. n58-12.
Table 2 | Free FA, TG and cholesterol levels and food intake of Bellomo Vegf-b-/- and littermate control mice on a Western-type diet
Age, diet, genotype free FA (mM) TG (mM) Cholesterol (mM) Food intake (g/day)
13w, SD,
wild type 0.34 6 0.04 0.9 6 0.09 3.5 6 0.09 -
Vegf-b-/- 0.35 6 0.04 n.s. 1.0 6 0.12 n.s. 3.6 6 0.11 n.s. -
31w, SD,
wild type 0.27 6 0.03 0.93 6 0.06 4.84 6 0.20 *** 3.2 6 0.3
Vegf-b-/- 0.25 6 0.01 n.s. 0.85 6 0.07 n.s. 5.20 6 0.18 n.s.,*** 3.3 6 0.2 n.s.
31w, WD,
wild type 0.28 6 0.03 1.15 6 0.05 7.09 6 0.35 *** 3.5 6 0.2
Vegf-b-/- 0.25 6 0.02 n.s. 1.15 6 0.03 n.s. 7.53 6 0.27 n.s.,*** 3.2 6 0.2 n.s.
n.s. non-significant compared to wild type of matching age and diet, *** p,0.001 compared to 13 week, standard diet, two-way ANOVA. Results are presented as means 6 S.E.M. n510–12
www.nature.com/scientificreports
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Figure 3 | Body weight and glucose metabolism in both Vegf-b-/- strains. (a). Response to intraperitoneal glucose tolerance test (IPGTT) after 15 weeks
on 60%HFD. (b) Area under IPGTT curve. The glucose dose was 1 mg/g body weight. (c). Intraperitoneal insulin tolerance test (IPITT) after 17 weeks of
60%HFD. The insulin dose was 0.75 mU/g bodyweight. (d). Bodyweight on 60%HFD at the time of IPGTT. (e).Western blot analysis of GLUT4protein
in the plasma membrane fraction of the heart and (f) skeletal muscle (n52).Blot images were cropped for comparison. Densitometry analysis of GLUT4
expression in wild type (white bars) and Vegf-b-/- (grey bars) mouse heart (e) or skeletal muscle (f) was performed using ImageQuant software. The
statistical analyses were performed with one-way ANOVA (a, b and d) or Student’s t-test (e and f). In (c) Kruskal-Wallis with Dunn’s post test with
significant differences indicated by: # AaseWT versus BellomoWT p,0.05, **AaseWT versus AaseVegf-b-/- p,0.01 and *AaseWTversus AaseVegf-b-/-
p,0.05 in (c). Results are expressed as mean 6 S.E.M. n56–13.
www.nature.com/scientificreports
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crossing has been less extensive as indicated by the observation of
grey coated mice in the progeny (18.2% of Aase Vegf-b-/- and Aase
littermate controls, unpublished observation M.H.D.), that is con-
sistent with 129 background in these mice. Within the 129 strains
significant genetic differences exist15. For example 129T2 mice have
lower insulin levels than C57BL/6 mice, yet they show no differences
in glucose tolerance16 whereas 129X1 mice display impaired glucose
tolerance but unaltered insulin levels, suggesting that the background
is a key determinant of metabolic phenotyping17. This emphasizes
the importance of thorough backcrossing of genetically modified
strains before metabolic phenotyping can be performed.
Overall we conclude here that Vegf-b is dispensable for cardiac
function, cardiac metabolism and HFD-induced metabolic state
under otherwise unstressed conditions.
Methods
Experimental animals. Bellomo Vegf-b-/- mice containing a beta-geo cassette11 in
C57Bl/6J and Aase Vegf-b-/-mice expressing neomycin resistance gene (NeoR)12 in
C57Bl/6N5 background were used in this study (see constructs Fig. 1c). Within the
strain, heterozygous mice were crossbred to obtain homozygotes and wild-type
littermate controls. Wild type littermate controls were included for both strains in all
experiments. Male mice were fed aWestern-type diet containing 42% of calories from
fat (TD.88137 Harlan Teklad, Indianapolis, IN, USA) from 14 weeks of age or a HFD
containing 60% of calories originating from fat (Research Diets, New Brunswick, NJ,
USA) from 5 weeks of age onwards. A group of BellomoVegf-b-/- mice with littermate
controls was maintained on a SD as an additional control. All animals had ad libitum
access to water and food and were maintained in standard housing conditions in the
Laboratory Animal Center of the University of Eastern Finland. All animal
procedures were approved by the Animal Experiment Board in Finland and carried
out according to the guidelines of the Experimental Animal Committee of the
University of Eastern Finland.
PCR and sequencing. Genomic DNA from Aase Vegf-b-/- and wild type littermate
control mice was isolated using the ChargeSwitch gDNA Micro Tissue kit (Thermo
Scientific, Waltham, MA, USA). The junction sites of the NeoR construct in the
mouse genomic DNA and the inserted construct itself were amplified with the
Phusion Flash High Fidelity Master Mix (Thermo Scientific, Waltham, MA, USA)
using forward sequencing primers: Aase F4 (59-cagtggtgccatggatagacg-39), New Aase
KO (59-gctattcggctatgactgggcac-39), NEO 39end (59-gaccgctatcaggacatagcgttg-39),
and reverse sequencing primers: New Aase KO (59-gtgcccagtcatagccgaatagc-39)
mVEGFB upstream from exon 5 (59-ggctctactctcagtcacctggtcc-39) and mVEGFB
exon 5 (59-cacctgtctggcttcacagcac-39). All primers were from Oligomer (Helsinki,
Finland). The PCR products were sub cloned into pBluescript II SK (Stratagene, Santa
Clara, CA, USA) and sequenced with the Applied Biosystems Dye Terminator (v.3.1)
sequencing kit (Haartman Institute sequencing unit, Helsinki). The obtained
sequencing results were analyzed by aligning them to reference sequences.
Genomic DNA from the hearts of Bellomo Vegf-b-/- mice was isolated using
standard Proteinase K based DNA extraction protocol. PCR for the junction sites of
the IRES-beta-GEO construct within the mouse genomic DNA was performed with
Phusion Flash High Fidelity enzyme (Thermo Scientific, Waltham, MA, USA) using
various primer pairs. The PCR products were sequenced with Applied Biosystems
3130xl Genetic Analyzer using the following primers: PCR1 from the original
Bellomo paper forward: (59-ccggagctcggcctccag-39), IRES reverse (59-
gttccgctgcctgcaaagggtc-39), b-geo forward (59-gacggcgaggatctcgtcgtg-39) and
mVEGFB intr6-7 reverse (59-gactgagtcactcactatatgtgaagc-39). Primers were from
Eurofins MWG Operon (Ebersberg, Germany). The obtained sequence data were
aligned to reference sequences to verify the correct insertion of the construct.
Echocardiography and electrocardiography. Echocardiography and ECG
measurements were done with a high-resolution imaging system Vevo 2100
(VisualSonics Inc., Toronto, ON, Canada) with a high-frequency ultrasound probe
(MS400) operating at 18–38 MHz. The measurements were done as described
earlier6.
Bodyweight, magnetic resonance imaging and food intake. Bodyweight was
monitored during the experiment every two to three weeks. MRI was performed on a
4.7 T magnet (Magnex Scientific, UK) interfaced with Varian UNITYINOVA console
(Varian Inc. Palo Alto, CA) using 60 mm quadrature volume transceiver (Rapid
Biomed, Rimpar, Germany) on 32 week old Bellomo Vegf-b-/- mice on Western-type
diet. Chemical-shift-selective 3D gradient echo sequence (TR/TE 100/12 ms,
resolution of 200 mm in transversal plane and 800 mm in B0 direction)18 was applied
to obtain coverage of the whole body. MR images were post-processed and automatic
water fat analysis was performed with lab built analysis program running on Matlab
platform18. The percentage of adipose tissue was calculated as fat area normalized to
water1 fat area. Furthermore, the fat mass per unit length (mg/mm ofmouse length)
was calculated. At sacrification three differentWATpads (perigonadal, subcutaneous
and renal) were dissected and weighed, together with heart, liver, kidney, pancreas
and intrascapular brown adipose tissue. For food intake animals were caged
separately and pre-weighed food was placed in the food choppers andmeasured every
three days. The daily intakewas calculated by food intake divided by themeasurement
time.
Tolerance tests. For IPGTT, animals onWestern-type diet were fasted overnight and
injected with 2 mg/g glucose (Sigma-Aldrich, St Louis, MO, USA) intraperitoneally.
IPITT were performed on non-fasted mice with 0.25 mU/g insulin (Actrapid, Novo
Nordisk, Denmark). On a 60% HFD IPGTT was performed on mice fasted for 2 h
with 1 mg/g glucose or IPITT after 1 h fasting with 0.75 mU/g insulin13. Pooled data
from $3 experiments are reported. Blood was collected from the tail vein in non-
anesthetized mice.
GLUT4 protein western blot.Heart and skeletal muscle samples were obtained fresh
from sacrificedmice following overnight fasting and 3 to 4 hours of refeeding. Plasma
membrane fractions of heart and skeletal muscle lysates were isolated by
centrifugating with 1000 g in a buffer containing 25 mM Tris, pH 7,4, 0,1 mM
EDTA, protease inhibitors and 0,25 M sucrose. Protein concentration was
determined by BCA kit (Thermo Scientific, Waltham, MA, USA). Five mg of protein
was run on SDS-PAGE and blotted to nitrocellulose membrane (BioRad, Hercules,
CA, USA). Primary GLUT4 antibody C-20 and HRP-conjugated secondary
antibodies were used for antibody staining (Santa Cruz Biotechnologies, CA, USA).
Immunolabeling was detected with ECL Plus detection system (GE Healthcare,
Fairfield, CT, USA).
Blood, serum and plasmametabolites.Glucose measurements were performed with
an Ascensia Elite XL (Bayer, Leverkusen, Germany) glucose meter. Glucose values
presented in the IPGTT graph on Western-type diet of Bellomo Vegf-b-/- mice were
determined microfluorimetrically18. For other blood metabolites plasma or serum
samples were taken from the saphenous vein after 17–18 h fasting. Serum free FAs
were determined using a colorimetric assay (WAKO, Osaka, Japan). Plasma
triglyceride (TG) levels and total cholesterol levels were measured colorimetrically
(Microlab 200 analyzer, Merck, Darmstadt, Germany). Plasma insulin levels were
determined by rat insulin ELISA kit (Crystal Chem, Downers, IL, USA).
Table 3 | Cardiac expression of glucose and FA metabolism related genes measured by RT-PCR
pathway/metabolism gene Aase WT Aase Vegf-b-/- Bellomo WT Bellomo Vegf-b-/-
glucose Pdha1 2.729 6 0.32 3.051 6 0.16 3.231 6 0.26 3.093 6 0.30
Pdk4 3.037 6 0.39 3.737 6 0.48 2.986 6 0.31 2.422 6 0.15
Glut4(Slc2a4) 2.603 6 0.28 3.064 6 0.18 2.969 6 0,32 3.005 6 0.23
FA oxidation Acadm 1.144 6 0.07 1.203 6 0.16 0.977 6 0.11 1.104 6 0.08
Acadl 1.244 6 0.12 1.293 6 0.17 1.022 6 0.12 1.181 6 0.09
Cpt1b 1.106 6 0.08 1.321 6 0.24 0.939 6 0.14 1.023 6 0.10
FA transport Fatp3(Slc27a3) 1.070 6 0.06 1.304 6 0.16 0.912 6 0.12 0.926 6 0.12
Fatp4(Slc27a4) 1.303 6 0.11 1.445 6 0.22 0.912 6 0.10 1.015 6 0.08
FA synthesis Fasn 1.110 6 0.08 1.135 6 0.15 0.891 6 0.11 1.005 6 0.08
co-factors Pgc-1a 2.521 6 0.45 3.026 6 0.16 3.350 6 0.36 2.954 6 0.39
Ncor1 2.497 6 0.40 3.145 6 0.26 3.496 6 0.26 3.527 6 0.58
Ppara 2.545 6 0.43 2.859 6 0.12 3.192 6 0.36 3.213 6 0.26
Pdha1,pyruvate dehydrogenase alpha 1; Pdk4, pyruvate dehydrogenase kinase, isozyme 4; Slc2a4/Glut4, glucose transporter 4; Acadm, acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain;
Acadl, acyl-Coenzyme A dehydrogenase, long chain; Cpt1b, carnitine palmitoyltransferase I beta; Slc27a3/Fatp3, fatty acid transport protein 3; Slc27a4/Fatp4, fatty acid transport protein 4; Fasn, fatty
acid synthase; Pgc-1a, peroxisome proliferator-activated receptor gamma, coactivator 1 alpha;Ncor1, nuclear receptor co-repressor 1; Ppara, peroxisome proliferator-activator receptor alpha. Messenger
RNA expression of indicated genes was normalized to B2M or PPIA. Results are expressed as mean 6 S.E.M. n55–7.
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Gene expression analysis. RNA was isolated from heart samples with TRI-Reagent
(Sigma-Aldrich, St Louis, MO, USA). RNA samples were DNAse treated by DNAse
Free kit (Thermo Fisher Scientific, Waltham, MA, USA) and reverse transcribed
using RevertaidTM (Thermo Fisher Scientific,Waltham,MA,USA). Quantitative PCR
was performed on a StepOnePlus Real-Time PCR system (Thermo Fisher Scientific,
Waltham, MA, USA). Relative mRNA expression of genes were measured using
specific Assays-on-Demand systems (Thermo Scientific, Waltham, MA, USA).
Expression levels were normalized to peptidylprolyl isomerase A (PPIA) or beta-2-
microglobilin (B2M).
Statistical tests.Data are reported as means 6 S.E.M. Data were checked for normal
distribution. In the case of multiple groups and when normally distributed, the data
were analyzed by one-way ANOVA with Bonferroni’s Multiple comparison post test
or two-way ANOVA. When not normally distributed Kruskal-Wallis test with
Dunn’s post test was used. In comparing two groups two-tailed Student’s t-test was
used. The statistical analyses and symbols used are reported in the figure legends.
Differences were considered statistically significant at p,0.05.
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